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Remifentanil combined with low-dose ketamine for post-
operative analgesia of lower limb fracture: a double-blind,
controlled study
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Objective:    To investigate the adjuvant effect of intra-
operative and postoperative low-dose ketamine administra-
tion to remifentanil consumption in patient-controlled anal-
gesia (PCA) for lower limb fracture.
Methods:    A total of 200 patients with lower limb frac-
ture receiving the surgery were randomly divided into 4
groups. In Groups A, B and C, patients received 0.5 mg/kg
ketamine infusion under general anesthesia, and ketamine
in a dose of 0.1 mg/ kg, 0.05 mg/kg, 0.01 mg/kg per hour
continuously for 24 hours after surgery, respectively. The
control group (Group D) received an equivalent volume of
normal saline only. With 20 µg/ml remifentanil in normal
saline, postoperative PCA was administered with a back-
ground infusion at 2 ml/h following 2 ml as a loading dose
and 1ml demand dose with a 3-minute lockout period.
Remifentanil consumption, 11-point visual analog scale
(VAS) scores, global satisfaction score (GSS), and side ef-
fects were also recorded by the acute pain service.
Results:    Cumulative PCA remifentanil consumption in
Groups A and B were (1378±377)  µg and (1531±402)  µg,
significantly lower than (1807±510)  µg and (1838±523)  µg in
Groups C and D (P< 0.01). VAS scores in Groups A and B were
significantly lower than those in Groups C and D (P< 0.01). In
the first 12 hours after operation, GSS was improved (P<0.01).
No respiratory depression was observed. No significant dif-
ference in side effects was observed among groups.
Conclusion:    Low-dose ketamine can relieve postop-
erative pain and moderately decrease remifentanil consump-
tion for PCA, with no obvious side effects of ketamine.
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Remifentanil, a new ultra-short-acting effectiveµ-opioid receptor agonist, is currently usedfor postoperative analgesia. However, its ad-
verse effects such as severe respiratory depression call
people’s concern.1  Considerable evidence is available
to support ketamine as an adjuvant to opioid for post-
operative analgesia.2 A small clinical study reported that
low-dose ketamine combined with remifentanil target-
controlled infusion might enhance the analgesic effect
and reduce respiratory depression.3 However, there are
few reports on the combination therapy of ketamine and
remifentanil for postoperative analgesia. This study in-
vestigated the effects of low-dose intraoperative and post-
operative ketamine administration to remifentanil con-
sumption for patient-controlled analgesia (PCA) after
the surgery for lower limb fracture.
METHODS
Approval of Human Ethics Committee of our hospi-
tal was procured and informed consent documents were
signed for all patients. Totally 200 patients who under-
went major surgery for lower limb fracture were involved.
Most patients (90%) had the fracture on the femur shaft.
The patients were randomly divided into 4 groups, and
the grouping was confidential to patients and relevant
hospital staff. The patients with pregnancy, breast
feeding, psychiatric disorders, chronic pain, chronic
opioid or ketamine usage, inability for PCA, or any other
contraindication to remifentanil/ketamine and participa-
tion in other research projects were excluded. The stan-
dardized analgesia was performed by the same anes-
thesiologists in the acute pain service (APS). Medica-
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tions were prepared in advance and transferred to the
anesthesiologist in the operating room and nurses in
the post-anesthesia care unit (PACU). Patients were
randomly divided into the following four groups. Patients
received intravenous infusion of 0.5 mg/kg ketamine in
anesthetic induction followed by the continuous
ketamine infusion in a dose of 0.1 mg/ kg, 0.05 mg/kg,
0.01 mg/kg per hour for the first 24 hours after surgery
in Groups A, B, and C, respectively, while an equiva-
lent volume of normal saline was infused in Group D
(control group).
All patients received PCA of  remifentanil (Ultiva®:
070302-2,  China) during the f irst  24 hours
postoperatively, with 20 µg/ml in normal saline, 2 ml as
a loading dose followed by a basal infusion at 2 ml/h,
and 1ml boluses with a 3-minute lockout period.
Nurses in the surgical ward and patients were in-
structed in APS using 11-point (0-10) visual analogue
scale (VAS) preoperatively. The use of a PCA system
(Grassby-9500, UK) was also explained. Anesthesia
was induced and maintained with propofol, remifentanil
and vecuronium. After surgery, all of them received
PACU management. A lateral forearm intravenous ac-
cess was made for administration of analgesics and
remifentanil was given to reduce VAS score by less
than 4. Other intraoperative or postoperative analgesics
were not permitted. Patients with inadequate analge-
sia had PCA boluses increased to 1.5 ml, and then the
basal infusion was increased to 3 ml/h if pain did not
relieve within 24 hours. If VAS at rest>4 persistently,
the patient quitted in this study and received other an-
algesic treatments. All analgesic interventions were
recorded.
In this study, global satisfaction score (GSS) was
recorded. The patients were asked about the postop-
erative analgesic effect of PCA system in the last 12
hours.  The responses were recorded: 1=very good, 2=
satisfactory, 3=average, 4=bad, and 5=very bad. As-
sessments were made 12 and 24 hours after operation.
PCA remifentanil consumption, VAS at rest and in
motion, vital signs, and the observer’s assessment of
alertness/sedative (OAA/S) scale were recorded every
4 hours for 24 hours. Movement pain was defined in
rolling, sitting, or coughing. Cognitive testing was per-
formed with the mini-mental state examination (MMSE)
before operation and 24 hours after operation, and the
time when the patients accomplished MMSE was
analyzed. Patients’ withdrawals and adverse effects in-
cluding postoperative nausea and vomiting, nightmare,
hallucinations, postoperative cognitive dysfunction  were
recorded.
Data were expressed as mean ± SD and analyzed
by SPSS 15.0 software for windows. The one-way analy-
sis of variance or Chi-square test was done. P<0.05 was
considered as significant difference.
RESULTS
With regards to the demographic and surgical data,
no statistically significant difference was observed be-
tween groups (P>0.05, Table 1).
PCA remifentanil consumption in Groups A and B
was less than those in Groups C and D (P<0.01), and
analgesic interventions in Groups C and D were more
frequent than those in Groups A and B (P<0.01, Table 2).
VAS scores in Groups A and B were lower than those in
Groups C and D at rest and in motion over 24 hours (P<0.01,
Table 3). The proportions of patients with GSS over 4 in
Groups A and B were larger than those in Groups C
and D during the first 12 hours (P<0.01). However, GSS
at 12-24 hours of  PCA showed no statistical signifi-
cance (P>0.05, Table 3).
As for adverse effects, 2 cases in each group had
serious postoperative nausea and vomiting and were
treated with intravenous infusion of 4 mg ondansetron.
And totally 10 female patients experienced temporal non-
phobic hallucinations (NPH, χ2=0.42, P>0.05), but did
not quit as they remained conscious.
There was no statistical significance in  heart rate (HR),
mean aortic pressure (MAP), respiration rate (RR),
MMSE scale, OAA/S scale, NPH and nightmares among
four groups (P>0.05, Table 5). No patients reported pho-
bic hallucinations, dizziness, postoperative cognitive
dysfunction, respiratory depression, pruritus and uri-
nary retention in this study. No death cases were re-
ported during the data collection period.
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Table 2. PCA remifentanil consumption (µg, χ ± s) and analgesic interventions
Groups (n=50)
     A
     B
     C
     D
  χ2/F
     P
PCA 0-12 h
747 ± 170
820 ± 182
928 ± 191
943 ± 204
F =17.07
   0.004
PCA 12-24 h
631 ± 127
710 ± 175
879 ± 193
895 ± 190
 F = 25.61
   < 0.001
PCA 0-24 h
1378 ± 377
1531 ± 402
1807 ± 510
1838 ± 523
   F =19.39
    0.003
Analgesic interventions (n)
                9
              10
               22
               24
          χ2=14.66
             0.005
Table 4. Global satisfaction score in each group (n, %)
Groups
(n=50)
PCA 0-12 h PCA12-24 h
I                         II                        III                       IV I                            II                              III
  A
  B
  C
  D
χ2
  P
35 (70%)
30 (60%)
18 (36%)
18 (36%)
10 (20%)
15 (30%)
14 (28%)
12 (24%)
 3 (6%)
 3 (6%)
 9 (18%)
11 (22%)
2 (4%)
2 (4%)
9 (18%)
9 (18%)
39 (78%)
38 (76%)
36 (72%)
  7 (14%)
34 (68%)
  8 (16%)
  7 (14%)
  8 (16%)
4 (8%)
4 (8%)
7 (14%)
8 (16%)
  39.44                                                                               1.36
  <0.001                                                                             0.799
Groups
(n=50)
Gender
(male/female)
Age (years) Weight (kg) Surgical position
Femoral
shaft
Hip joint
Preoperative
MMSE
Perioperative
remifentanil dose
(µg)
Time in
PACU (min)
  A
  B
  C
  D
χ2/F
  P
  28 / 22
  25 / 25
  30 / 20
  32 / 18
χ2= 2.95
  0.723
49.5 ± 4.9
49.7 ± 5.7
49.7 ± 6.1
50.1 ± 6.3
  F = 1.07
   0.365
54.7 ± 11.0
55.5 ± 10.0
56.0 ± 10.0
56.7 ± 10.0
   F = 1.71
    0.322
48
49
48
  2
  2
  1
45
  5
χ2 = 4.59
    0.204
26.5 ± 2.5
   27 ± 2.5
26.8 ± 2.5
27.0 ± 2.5
  F = 1.97
  0.307
   799 ± 263.5
787.2 ± 266.1
786.4 ± 265.7
   768 ± 272.1
      F = 1.16
      0.349
64.3 ± 10.1
63.3 ± 11.7
63.5 ± 9.8
61.7 ± 12.0
  F = 2.03
  0.299
Table 1. Clinical data (χ ± s)
Table 3. VAS pain scores at the first 24 hours after operation (χ ± s)
Groups
(n=50)
VAS at rest VAS in motion
Mean VAS VAS-max Time of VAS-
max (min)
Period of VAS
>3 (min)
Mean VAS VAS-max Time of VAS-
max (min)
Period of
VAS >3 (min)
A
B
C
D
F
P
1.2 ± 0.6
1.2 ± 0.8
2.0 ± 1.0
2.0 ± 1.0
  18.33
    0.004
2.8 ± 1.2
3.0 ± 1.6
4.0 ± 1.6
4.1 ± 1.6
 13.66
   0.007
  9.2 ± 4.3
10.0 ± 3.7
16.6 ± 5.4
16.5 ± 6.0
   36.85
   <0.001
  9.8 ± 4.0
  9.8 ± 2.7
12.0 ± 4.0
12.0 ± 5.2
   10.96
     0.008
3.5 ± 1.2
3.7 ± 1.6
4.7 ± 1.6
4.7 ± 1.5
 15.25
   0.006
4.6 ± 2.5
5.0 ± 2.4
7.0 ± 3.0
7.2 ± 3.0
 16.49
   0.006
13.5 ± 5.0
15.0 ± 5.0
23.8 ± 5.4
24.0 ± 7.2
  57.81
  <0.001
16.0 ± 4.9
18.0 ± 5.4
27.0 ± 6.0
29.5 ± 8.0
   76.27
   <0.001
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DISCUSSION
Recent studies have reported perioperative ketamine
administration for acute postoperative pain management
in Europe and USA.2, 4, 5 However, there are few reports
on ketamine combined with remifentanil for postopera-
tive analgesia. Our study has demonstrated that the
application of ketamine as adjuvants can obviously en-
hance analgesic effect, decrease cumulative remifentanil
consumption and reduce the intervention after the sur-
gery of lower limb fracture. With the increase of ketamine
administration, this effect is more obvious. Meanwhile,
al though some pat ients had nightmares or
hallucinations, no postoperative cognitive dysfunction
was found.
Ketamine at subanesthesic dose is a relatively se-
lective N-methyl-D-aspartate (NMDA) receptor
antagonist. In this study, VAS scores in Groups A and
B were moderately decreased and the dosage of
remifentanil in PCA was mildly decreased, which was
consistent with the previous studies.5,6 During the first
12 hours of PCA, in Groups A and B, the number of
patients with GSS=1 increased, while VAS and
remifentani administration were decreased.  These re-
sults indicate that ketamine enhances the analgesic
effect of opioid. And the similar result has been reported
in the literature.2,4-6 It also suggests that the moderate
reduction of VAS has clinical significance. However,
similar GSS were observed in all groups at 12 to 24
hours of PCA, which may be related to the fluctuations
in plasma concentration of ketamine.
How can ketamine reduce the consumption of
remifentanil? We thought that ketamine can directly
reduce surgical trauma-induced hyperalgesia and pre-
vent perioperative opioid-induced hyperalgesia and acute
tolerance.5, 7 Accordingly, ketamine at less than 10% of
the dose for clinical anesthesia could be used for post-
operative analgesia.8 Research has shown that the com-
bination therapy of remifentanil and ketamine infusion
with the similar infusion rate in our study could signifi-
cantly reduce hyperalgesia and the consumption of
morphine.9 However, Engelhardt et al 10 found that the
combination of remifentanil with small-dose ketamine
(4 µg·kg-1·min-1 after 0.5 mg/kg boluses) had no influ-
ence on postoperative analgesia, which may be due to
that the drugs were only used during operation. In our
study, ketamine was infused continuously in the first
24 hours after operation, but in small-dose ketamine
group (Group C), remifentanil comsumption decreased
by 1.69% because of the lower ketamine infusion rate.
In sub-anesthetic dose group (Groups A and B),
remifentanil consumption was reduced by 25.03% in
Group A and 16.7% in Group B, respectively, which
improved the postoperative pain management, and sig-
nificantly reduced analgesic intervention of APS. In
addition, the infusion of ketamine at 0.12 mg/kg per hour
combined with sufentanil or fentanyl can produce the
satisfactory analgesic effect in patients undergoing or-
thopedic surgery.11
We should take adverse effects into account when
selecting the infusion rate and duration of ketamine. A
review reported that ketamine could reduce the mor-
phine dosage and the occurrence of postoperative nau-
sea and vomiting in the postoperative analgesia.2
However, in this study, we did not observe that ketamine
could reduce the adverse effects of remifentanil. On one
hand, 8 patients needed antiemetic drugs, which might
be caused by many risk factors such as female gender,
non-smokers, case history of kinesia or postoperative
vomiting, postoperative use of opioids and / or ketamine,
etc. It is important to identify and prevent common risk
factors of postoperative nausea and vomiting.12 On the
other hand, ketamine did not aggravate the adverse ef-
87.0 ± 9.8
85.7 ± 9.9
86.2 ± 9.6
84.9 ± 9.0
  F = 1.03
  0.370
18.0 ± 1.2
18.0 ± 1.2
17.9 ± 1.2
17.8 ± 1.2
  F = 1.67
  0.325
 Groups (n=50)          HR (bpm)               MAP (mmHg)           RR (rpm)           OAA/S             MMSE         NPH (n, %)      Nightmare (n, %)
13 (26%)
  9 (18%)
10 (16%)
  8 (16%)
χ2 = 1.75
    0.759
  A
  B
  C
  D
χ2/F
  P
 70.3 ± 5.0
69.9 ± 5.8
70.1 ± 6.2
68.5 ± 6.7
  F = 1.59
  0.331
 4.3 ± 1.2
4.4 ± 1.3
4.4 ± 1.4
4.5 ± 1.4
  F = 1.51
  0.333
27.5 ± 2.2
27.9 ± 2.4
27.9 ± 2.5
28.2 ± 2.5
  F =2.09
  0.305
  3 (6%)
  2 (4%)
  2 (4%)
  3 (6%)
χ2 =0.42
    0.875
Table 5. HR, MAP, RR, OAA/S Scale, MMSE Scale, NPH and nightmare after surgery (χ ± s)
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fects of remifentanil. To be noticed, systemic opioid
administration may cause severe respiratory depression,
apnea or chest muscular stiffness. Under the condition
of air breathing, the intravenous injection of 25-200 µg
remifentanil may cause a temporal apnea or oxygen
saturation≤ 90%.13 The continuous infusion of
remifentanil at the rate of 0.05 µg·kg-1·min-1 induced
serious respiratory depression (3/28, 10.7%), but se-
vere respiratory complications were not observed in our
study, which indicated that ketamine had antagonistic
effect with remifentanil in respiratory depression rather
than synergic or additive effect.3,14 Approximately 20%
of patients in this study experienced nightmares. Only
10 cases of female patients suffered from non-phobic
hallucinations without postoperative cognitive
dysfunction. MMSE assessment showed that there was
no statistical significance among four groups in post-
operative cognitive function. Meanwhile, the OAA/S
scale was over 4 in this study. No dizziness, emotional
distress, phobic hallucinations, pruritus, urinary reten-
tion and other side effects were observed. No PCA
equipment failure occurred. These results also con-
firmed that with the specific monitoring and effective
analgesia techniques, APS can promote the pain man-
agement and benefit both the patients and medical staff.
Until now, there was no pharmacologic evidence to
support mixing ketamine and remifentanil together. So
an additional infusion device for ketamine was required
in the experimental groups.
In summary, low-dose ketamine can improve post-
operative analgesia with a moderate decrease of PCA
remifentanil consumption, and no significant side ef-
fects of ketamine are observed. Nevertheless, further
research is needed to confirm the current findings.
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